News | February 11, 2021
SMS Pharmaceuticals Q3FY21 consolidated PAT up to Rs. 21.39 Cr
The company posted net profit of Rs.7.61 crores for the period ended December 31, 2019.
The company posted net profit of Rs.7.61 crores for the period ended December 31, 2019.
The company posted net profit of Rs.62.17 crores for the period ended December 31, 2019.
The company posted net loss of Rs. 661.16 crores for the period ended December 31, 2019.
The company has reported total income of Rs.25699.68 crores during the 9 months period ended December 31, 2020.
Senores Pharmaceuticals (SPI) acquired 51% stake in Zoraya Pharmaceuticals
Orphan drug designation (ODD) by the USFDA for Desidustat, provides eligibility for a potential seven-year marketing exclusivity subject to the USFDA approval
Exemestane is a key therapeutic used in the treatment of certain types of breast cancer in postmenopausal women
RedHill has obtained a court-approved asset attachment in South Korea to prevent Kukbo from transferring or disposing of assets ahead of enforcement of the judgment
Speakers are: Dr. Alok Khullar, Senior Technology Leader, Pidilite Industries; Dr. Kamlesh Pai Fondekar, Head - R&D, Godrej Agrovet; Dr. Hiten Mehta, Head - R&D (Chlor-Alkali), Aditya Birla Chemicals; Dr. Anil Kumar Soni, Head - Application Development, R&D, Clariant Chemicals India; Dr. Rupak Paul, Deputy General Manager – Formulation, Rallis India; Dr. Manish M. Khandagale, Senior Field Application Specialist, Revvity Signals; and Pravin Prashant, Executive Editor, Indian Pharma Post
Budesonide is indicated for mild to moderate active Crohn's disease involving the ileum and/or the ascending colon in adults and children 8 years of age and olde
Subscribe To Our Newsletter & Stay Updated
